Niagen Bioscience is trading at $3.18 (-8.36%) after hours following second-quarter results that disappointed on the top line.
- The company reported $29.8 million in net sales, missing analyst expectations, even as diluted EPS of $0.01 met consensus estimates.
- Strong 23% year-over-year growth in the direct-to-consumer (DTC) channel was offset by significant weakness in the B2B ingredient segment.
- The decline appears driven specifically by the earnings miss rather than broader market sentiment, as major indexes trended higher in a risk-on environment.